BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25048089)

  • 1. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review.
    Sheff KW; Hoda MA; Dome B; Hegedus B; Klepetko W; Weiss GJ
    Microrna; 2012; 1(1):40-8. PubMed ID: 25048089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
    Liu H; Wu L; Ji K; Wang W
    Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
    Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
    Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
    Bibby AC; Tsim S; Kanellakis N; Ball H; Talbot DC; Blyth KG; Maskell NA; Psallidas I
    Eur Respir Rev; 2016 Dec; 25(142):472-486. PubMed ID: 27903668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Malignant pleural mesothelioma].
    Sritharan SS; Frandsen JL; Omland Ø; Bruun JM
    Ugeskr Laeger; 2018 Apr; 180(15):. PubMed ID: 29690982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in treatment of mesothelioma.
    Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
    Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for immunotherapy in malignant pleural mesothelioma?
    Tartarone A; Lerose R; Aieta M
    Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-asbestos-related malignant pleural mesothelioma.
    Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
    Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
    Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].
    Multidisciplinary Committee of Oncology, Chinese Physicians Association
    Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma.
    Woolhouse I; Maskell NA
    Thorax; 2018 Mar; 73(3):210-212. PubMed ID: 29444989
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
    Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
    J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of microRNAs in malignant mesothelioma.
    Truini A; Coco S; Alama A; Genova C; Sini C; Dal Bello MG; Barletta G; Rijavec E; Burrafato G; Boccardo F; Grossi F
    Cell Mol Life Sci; 2014 Aug; 71(15):2865-78. PubMed ID: 24562347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant pleural mesothelioma: diagnosis and treatment].
    Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
    Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.